Company Name, Ticker, Suppliers, else..

Cti Biopharma Corp (NASDAQ: CTIC)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Cti Biopharma 's

Name: Cti Biopharma Corp Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CTIC Sales vs. its Competitors Q1 2023

Comparing the current results to its competitors, Cti Biopharma reported Revenue increase in the 1 quarter 2023 by 950.81 % year on year, while most of its competitors have experienced contraction in revenues by -1.13 %, achieved in the same quarter.

• List of CTIC Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Cti Biopharma Corp recorded a net loss, despite income increase by most of its competitors of 0 %

<< CTIC Stock Performance Comparisons

<< See the full list of CTIC competitors

Overall company Market Share Q1 2023

Due to outstanding performance in Overall company, revenue grew by 950.81 % Cti Biopharma Corp improved its market share, to approximately 0.19 %. << More on CTIC Market Share.

*Market share is calculated based on total revenue.

CTIC's Stock Performance relative to its Competitors

Publicly Traded Peers of Cti Biopharma Corp

Apexigen Inc
Share Performance

-10.44%

30 Days

Apexigen Inc

Profile

Apexigen Inc's business model revolves around developing and commercializing novel antibody-based therapeutics. They focus on discovering and optimizing antibody drugs through their proprietary technology platforms. By partnering with pharmaceutical companies or utilizing their own resources, they aim to provide innovative solutions for treating various diseases and improving patients' lives.

More about Apexigen Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9.522 mill.	$ - mill.	$ -40.039 mill.

89bio Inc
Share Performance

+0.27%

Over The Past 5 Days

89bio Inc

Profile

89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions.

More about 89bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,342.942 mill.	$ - mill.	$ -450.206 mill.

Genelux Corporation
Share Performance

-23.44%

One Year

Genelux Corporation

Profile

Genelux Corporation's business model revolves around the development and commercialization of innovative genetic-based therapies and technologies.

More about Genelux Corporation's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 113.909 mill.	$ - mill.	$ -33.581 mill.

Inhibitor Therapeutics Inc
Share Performance

0.00%

This Quarter

Inhibitor Therapeutics Inc

Profile

Inhibitor Therapeutics Inc's business model focuses on developing and commercializing innovative inhibitors for targeted therapies.

More about Inhibitor Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 15.043 mill.	$ - mill.	$ -3.308 mill.

Ibio inc
Share Performance

+56.17%

One Year

Ibio inc

Profile

Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.

More about Ibio inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 131.636 mill.	$ - mill.	$ -33.044 mill.

87 more competitors available

Sources: Cti Biopharma Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, August 31, 2026 4:59 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cti Biopharma Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.